ATI-2138
- Generic Name
- ATI-2138
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06585202
- Locations
- 🇺🇸
Aclaris Investigational Site, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath